Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

PHASE1CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 14, 2009

Primary Completion Date

June 26, 2012

Study Completion Date

December 5, 2013

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

eltrombopag olamine

thrombopoietin receptor agonist

OTHER

Placebo

Placebo tablets with no active pharmaceutical ingredient

Trial Locations (65)

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

404

GSK Investigational Site, Taichung

500

GSK Investigational Site, Changhua

2100

GSK Investigational Site, Koebenhavn Oe

5000

GSK Investigational Site, Odense C

10461

GSK Investigational Site, The Bronx

12200

GSK Investigational Site, Berlin

13273

GSK Investigational Site, Marseille

14033

GSK Investigational Site, Caen

15224

GSK Investigational Site, Pittsburgh

19104

GSK Investigational Site, Philadelphia

19106

GSK Investigational Site, Philadelphia

21231

GSK Investigational Site, Baltimore

22031

GSK Investigational Site, Fairfax

22205

GSK Investigational Site, Arlington

25030

GSK Investigational Site, Besançon

29601

GSK Investigational Site, Greenville

30341

GSK Investigational Site, Atlanta

31059

GSK Investigational Site, Toulouse

33065

GSK Investigational Site, Coral Springs

33467

GSK Investigational Site, Lake Worth

35294

GSK Investigational Site, Birmingham

36100

GSK Investigational Site, Vicenza

37075

GSK Investigational Site, Göttingen

38120

GSK Investigational Site, Memphis

40225

GSK Investigational Site, Düsseldorf

47166

GSK Investigational Site, Duisburg

48202

GSK Investigational Site, Detroit

50134

GSK Investigational Site, Florence

50937

GSK Investigational Site, Cologne

53705

GSK Investigational Site, Madison

55131

GSK Investigational Site, Mainz

63110

GSK Investigational Site, St Louis

64109

GSK Investigational Site, Bayonne

64128

GSK Investigational Site, Kansas City

70199

GSK Investigational Site, Stuttgart

75571

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

78130

GSK Investigational Site, New Braunfels

78229

GSK Investigational Site, San Antonio

81675

GSK Investigational Site, Munich

89081

GSK Investigational Site, Ulm

89100

GSK Investigational Site, Reggio Calabria

90404

GSK Investigational Site, Santa Monica

93009

GSK Investigational Site, Bobigny

94305

GSK Investigational Site, Stanford

02111

GSK Investigational Site, Boston

08103

GSK Investigational Site, Camden

41253-190

GSK Investigational Site, Salvador

30130-100

GSK Investigational Site, Belo Horizonte

20211-030

GSK Investigational Site, Rio de Janeiro

20230 -130

GSK Investigational Site, Rio de Janeiro

01307

GSK Investigational Site, Dresden

Unknown

GSK Investigational Site, Hong Kong

GSK Investigational Site, Shatin, New Territories

00927

GSK Investigational Site, San Juan

135-710

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

AB25 2ZN

GSK Investigational Site, Aberdeen

G12 0YN

GSK Investigational Site, Glasgow

LS9 7TF

GSK Investigational Site, Leeds

SE5 9RS

GSK Investigational Site, London

SW17 0RE

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00903422 - Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | Biotech Hunter | Biotech Hunter